Published in J Investig Med High Impact Case Rep on June 08, 2017
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia (2009) 10.95
Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care (2006) 7.99
New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care (2009) 6.17
Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer (2005) 6.06
Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care (2009) 2.90
Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur J Cancer (2011) 2.59
Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology (2008) 2.58
Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol (2004) 2.12
Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res (1995) 1.89
The relationship between diabetes and pancreatic cancer. Mol Cancer (2003) 1.72
Diabetes and pancreatic cancer. Mol Carcinog (2012) 1.71
Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg (1993) 1.62
Sulphonylureas and cancer: a case-control study. Acta Diabetol (2008) 1.56
Inflammation and pancreatic cancer: an evidence-based review. Curr Opin Pharmacol (2009) 1.46
Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Am J Pathol (2003) 1.45
Insulin-like growth factor I and transforming growth factor alpha as autocrine growth factors in human pancreatic cancer cell growth. Cancer Res (1990) 1.38
Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in β cells and mice. Gastroenterology (2012) 1.34
Physiological concentrations of insulin augment pancreatic cancer cell proliferation and glucose utilization by activating MAP kinase, PI3 kinase and enhancing GLUT-1 expression. Pancreas (2000) 1.33
Clinical review 63: Diabetes and pancreatic cancer: clues to the early diagnosis of pancreatic malignancy. J Clin Endocrinol Metab (1994) 1.25
Putative pancreatic cancer-associated diabetogenic factor: 2030 MW peptide. Pancreas (2002) 1.22
Diabetes mellitus in pancreatic cancer follow-up. Anticancer Res (1995) 1.19
Requirement of different signaling pathways mediated by insulin-like growth factor-I receptor for proliferation, invasion, and VPF/VEGF expression in a pancreatic carcinoma cell line. Biochem Biophys Res Commun (2003) 1.02
The intracellular mechanism of insulin resistance in pancreatic cancer patients. J Clin Endocrinol Metab (2000) 1.00
Effect of insulin-like growth factor gene polymorphisms alone or in interaction with diabetes on the risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev (2008) 0.97
Diabetes: risk factor for the development of pancreatic cancer or manifestation of the disease? World J Surg (2001) 0.97
Association of diabetes mellitus and pancreatic adenocarcinoma: a meta-analysis of 88 studies. Ann Surg Oncol (2014) 0.95
Impaired insulin action on phosphatidylinositol 3-kinase activity and glucose transport in skeletal muscle of pancreatic cancer patients. Pancreas (2003) 0.94
CA19-9 as a screening and diagnostic tool in symptomatic patients: the Japanese experience. Pancreas (1994) 0.94
Short-term consumption of a high-sucrose diet has a pro-oxidant effect in rats. Br J Nutr (2002) 0.91
Genetic determinants of diabetes are similarly associated with other immune-mediated diseases. Curr Opin Allergy Clin Immunol (2007) 0.84